Stay updated with breaking news from Hematologic Neoplasms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings on the mechanism of action from the BOXR CAR-T platform indicate improved metabolic function and preservation of early memory subsets of T cells SOTIO anticipates initiating first-in-human DUET-01 trial for lead CAR-T cell therapy candidate, BOXR1030, in coming monthsPhase 2 AURELIO-04 combination study of...
LONDON, United Kingdom and LEIDEN, The Netherlands, February 22, 2021 / B3C newswire / --NovalGen Ltd. (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V. (“HALIX”), a contract development and manufacturing organisation, today announced a strategic partnership. Within the scope of this partnership, HALIX will provide manufacturing of clinical supply of NovalGen’s therapies. NovalGen’s innovative platform technology has been successfully deployed at HALIX to manufacture clinical trial material for NovalGen’s first clinical progr...